Ceapro Inc., a biotechnology company, engages in developing and commercializing active ingredients in the United States, Canada, Germany, China, and internationally. The company is involved in the development and application of technology to the production of extracts and active ingredients from oats and other renewable plant resources. It adds value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company's products include natural active ingredients comprising beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; natural anti-aging skincare products; and veterinary therapeutic products, such as oat shampoos, ear cleansers, and dermal complexes/conditioners. Its products and technologies that are under research and development, or pre-commercial stage comprise a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; various novel enabling technologies, including Pressurized Gas eXpanded drying technology; and new oat variety and technologies to enhance the content of avenanthramides. The company was founded in 1997 and is headquartered in Edmonton, Canada.
Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol CV:CZO.
$0.53 OTCQX
As of 01/27/2023 OTCMarkets
2022 © Stock Market MBA, Inc.